Recent news on Gm-Csf

Micromet, Nycomed GM-CSF Deal Could Be Worth ?125M  -  25 May 2007
Therapeutics Daily (subscription) (press release),...the GM-CSF neutralizer better odds against a similar antibody already in Phase I/II trials against rheumatoid arthritis by KaloBios Pharmaceuticals Inc.

Topigen Presents New Data on Its Phase II Asthma Product, TPI ASM8 ...  -  May 23, 2007
PipelineReview.com (press release),...the persistence of allergic inflammatory cells via interference with a common beta sub-unit for the receptors of interleukin (IL) 3, 5 and GM-CSF.

Humanised mouse 'far more useful' to predict side effects  -  May 22, 2007
LabTechnologist.com,This is done by combining two genes together: the granulocyte-macrophage colony-stimulating factor (GM-CSF) gene to attract antigen-presenting cells to

Cell Genesys Provides Update on Clinical Program for GVAX ...  -  May 10, 2007
PipelineReview.com (press release),The products are comprised of tumor cells that have been modified to secrete GM-CSF, an immune stimulatory hormone, and then irradiated for safety.

Favrille Reports First Quarter 2007 Financial Results  -  May 10, 2007
Genetic Engineering News (press release),This agreement helps pave the way for commercialization, including reimbursement, of FavId in combination with Berlex's Leukine(R) (sargramostim, GM-CSF),

The alcoholic lung: epidemiology, pathophysiology, and potential ...  -  Apr 11, 2007
AJP-Lung Physiology (subscription)Impaired GM-CSF signaling in the alcoholic lung. Granulocyte/macrophage colony-stimulating factor or GM-CSF is a 23-kDa glycosylated monomeric peptide

Cell Genesys immunotherapy is patiently specific  -  Apr 19, 2007
LabTechnologist.com,The cells secrete the immune stimulatory hormone, GM-CSF (granulocyte-macrophage colony stimulating factor) to encourage immune cells to attack cancer cells

New therapy attacks multiple sclerosis on two fronts  -  Apr 11, 2007
DrugResearcher.com,...that prevents the production of pro-inflammatory cytokines such as pro-inflammatory cytokines like Interferon-gamma, IL-2, IL-3, TNF-alpha and GM-CSF.

Donald Metcalf Receives American Association for Cancer Research  -  Apr 4, 2007
WebWire (press release),Exploiting this, his collaborators documented the effectiveness of GM-CSF and G-CSF (two primary white blood cell regulators) when injected into patients.

Vaccines Everywhere  -  Apr 3, 2007
Corante,Both of these vaccines depend on production of GM-CSF secreting cells (a powerful cytokine which stimulates white blood cell production and activity),

FDA Panel Recommends Approval of Therapeutic Prostate Cancer Vaccine  -  Mar 30, 2007
MedPage Today,...are obtained from patients by leukopheresis and activated in vitro with a recombinant fusion protein (prostatic acid phosphatase fused with GM-CSF).

Cell Genesys reports data from clinical trials of GVAX ...  -  Apr 18, 2007
News-Medical.net,GVAX immunotherapy for prostate cancer is comprised of two prostate cancer cell lines that have been modified to secrete GM-CSF (granulocyte-macrophage

Cell Genesys shares soar over promising cancer immunotherapy data  -  Apr 4, 2007
Pharma Times (subscription),GVAX immunotherapy is comprised of two prostate cancer cell lines that have been modified to secrete GM-CSF (granulocyte-macrophage colony stimulating

Researchers Discover Genetic Locus Linked to Schizophrenia Risk  -  Mar 28, 2007
Genetic Engineering News (press release),Those two genes produce receptors for two cytokines, GM-CSF and interleukin-3. “A role for cytokines could help explain why prenatal exposure to viruses is

Genetic Risk For Schizophrenia Uncovered By Feinstein Researchers  -  27 Mar 2007
Medical News Today (press release),Those two genes produce receptors for two cytokines, GM-CSF and interleukin-3. Cytokines are involved in the body's response to infection, and may play a

Breast cancer chemo can carry leukemia risk  -  Mar 16, 2007
The Australian,Growth factors such as G-CSF (granulocyte colony-stimulating factor), and GM-CSF (granulocyte-macrophage colony-stimulating factor) boost the patient's

Drugs to boost immune system during chemo may hike risks  -  Mar 5, 2007
Jackson Clarion Ledger,Growth factors such as G-CSF, known by the trade name Neupogen, and GM-CSF boost the patient's production of white blood cells.

Topigen Initiates Expanded PHASE II Trial of Inhaled TPI ASM8 In ...  -  Mar 9, 2007
PharmaLive.com (press release),...the persistence of allergic inflammatory cells via interference with a common beta sub-unit for the receptors of interleukin (IL) 3, 5 and GM-CSF.

Medarex Announces 2006 Fourth Quarter and Year End Financial Results  -  Feb 28, 2007
PR Newswire (press release),...such as GM-CSF or the Cell Genesys, Inc. product, GVAX(R), at the annual meeting of the American Society of Clinical Oncology (ASCO); - Announcing at

Cell Genesys and Medarex Announce Encouraging Follow-Up Results ...  -  Feb 26, 2007
Drug Newswire (press release),GVAX immunotherapy for prostate cancer is comprised of two prostate cancer cell lines that have been modified to secrete GM-CSF (granulocyte-macrophage

Role of Granulocyte Macrophage Colony-Stimulating Factor in Host ...  -  Feb 23, 2007
Am J Pathology (subscription)We investigated the role of granulocyte macrophage colony-stimulating factor (GM-CSF) in host defense in a murine model of pulmonary cryptococcosis induced

GM-CSF Autoantibodies and Neutrophil Dysfunction in Pulmonary ...  -  Feb 7, 2007
New England Journal of Medicine (subscription),We tested the hypothesis that neutrophil functions are impaired in patients with pulmonary alveolar proteinosis and that GM-CSF autoantibodies cause the

Favrille Announces Agreement With Berlex, Inc. Regarding Use of ...  -  Feb 14, 2007
PharmaLive.com (press release),Leukine is a recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF), a growth factor that is currently used to help fight infections in

Growth Factors Given With Chemotherapy Associated With Increased ...  -  Feb 9, 2007
Medical News Today (press release),The growth factors granulocyte or granulocyte-macrophage colony-stimulating factor (G-CSF or GM-CSF) have been used to reduce the risk of infections from

Cincinnati Researchers Publish Pioneering Work Characterizing The ...  -  Feb 9, 2007
Medical News Today (press release),..."In addition to illuminating the mechanism of this disorder, these results provide support for the feasibility of therapies that modulate GM-CSF activity to

Growth Factors Associated with Neutrophil Function  -  Feb 8, 2007
MedPage Today,One implication is that monoclonal antibodies to GM-CSF might be useful to treat patients with chronic inflammatory disorders, Dr. Uchida and colleagues

Immunity Boosters May Raise Leukemia Risk  -  Feb 6, 2007
CBS News,But 1.77 percent of the women treated with G-CSF or GM-CSF developed leukemia. Statistically, the drugs seemed to double a woman's leukemia risk—although

Favrille Reports Fourth Quarter and Year End 2006 Financial Results  -  Feb 18, 2007
Drug Newswire (press release),Leukine is a. appropriate patients by enhancing immune cell function. GM-CSF has. trials of active immunotherapies. GM-CSF was first used in an early

Favrille Reports Fourth Quarter and Year End 2006 Financial Results  -  Feb 15, 2007
Genetic Engineering News (press release),While terms of the agreement were not disclosed, the focus is on studying the use of FavId in conjunction with Berlex's Leukine (sargramostim, GM-CSF) in

Cell Genesys And Medarex Announce Encouraging Follow-Up Results ...  -  Feb 23, 2007
Medical News Today (press release),GVAX immunotherapy for prostate cancer is comprised of two prostate cancer cell lines that have been modified to secrete GM-CSF (granulocyte-macrophage

Cell Genesys and Medarex Announce Encouraging Follow-Up Results ...  -  Feb 22, 2007
PharmaLive.com (press release),GVAX immunotherapy for prostate cancer is comprised of two prostate cancer cell lines that have been modified to secrete GM-CSF (granulocyte-macrophage

Infection-Fighting Cancer Treatment Could Boost Leukemia Risk  -  Feb 7, 2007
Atlanta Journal Constitution (subscription),Of the total, 906 women received either granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF), or both.

Risk still low on drugs to aid immunity  -  Feb 7, 2007
Chicago Tribune,Growth factors such as G-CSF (granulocyte colony-stimulating factor), known by the trade name Neupogen, and GM-CSF (granulocyte-macrophage

AUDIO SUMMARY  -  Feb 7, 2007
New England Journal of Medicine (subscription),Featured are articles on clomiphene, metformin, or both for infertility in the polycystic ovary syndrome; GM-CSF autoantibodies and neutrophil dysfunction

Growth Factors for Breast Cancer Linked to Leukemia  -  Feb 7, 2007
MedPage Today,...colony stimulating factor (G-CSF) or granulocyte-macrophage colony stimulating factor (GM-CSF) is 2.14, compared to women who don't get the cytokines,

Cancer support care may up blood diseases  -  Feb 6, 2007
United Press InternationalSixteen percent of the patients were treated with growth factors G-CSF, GM-CSF, or both. The researchers said the increase in the blood disorders might be

Spying on possible polonium therapies  -  Feb 6, 2007
In-PharmaTechnologist.com,Canadian company Cangene develop Leucotropin (GM-CSF) for the treatment of ARS. GM-CSF is a protein that stimulates the production of infection-fighting

Pig Clones to Come En Masse  -  Jan 11, 2007
Korea Times,The cloned piglets are expected to secret GM-CSF in their millk, a protein that stimulates the bone marrow to produce several kinds of white blood cells and

New Vaccine Stimulates Colorectal Cancer Patient's Immune Systems ...  -  Jan 1, 2007
Science Daily (press release)About 70 percent of patients produced both TNF-alpha and GM-CSF -- a protein that stimulates white blood cell production -- in response to both the vaccine

Market Report -- In Play (TELK)  -  Dec 11, 2006
MSN MoneyTelik announces positive data demonstrating that TELINTRA enhances production of G-CSF and GM-CSF Co reports positive preclinical data demonstrating that ...

Telik Announces Positive Data Demonstrating That TELINTRA(TM) ...  -  Dec 11, 2006
Medical News Today (press release),The company reported that neutrophil recovery was also mediated and preceded by significantly increased levels of G-CSF and GM-CSF. ...

Rituxan® plus Leukine® Promising for Low-grade Lymphomas  -  Dec 11, 2006
Cancer Consultants (press release),2006 annual Chemotherapy Foundation Symposium, the treatment combination consisting of Rituxan® (rituximab) plus Leukine® (sargramostim, GM-CSF) is effective ...

Telik Announces Positive Data Demonstrating that  -  Dec 9, 2006
FinanzNachrichten.de,Recombinant G-CSF and GM- CSF are the current standards of care for the treatment of cancer patients with chemotherapy-induced neutropenia. ...

Positive Phase II Clinical Trial Results with HER2/neu Vaccine  -  Dec 15, 2006
NDTV.com,E75 is administered as a vaccine consisting of the peptide mixed with GM-CSF (sargramostim or Leukine(R)) as an immunoadjuvant and administered intradermally ...

HER2 Vaccine May Help Reduce Recurrences in Breast Cancer  -  Dec 14, 2006
Cancer Consultants (press release),Due to its promising immune-stimulatory properties, researchers derived a vaccine utilizing the E75 peptide, mixed with GM-CSF, for intradermal administration. ...

Rituxan® and Leukine® Promising for Low-Grade Lymphomas  -  Dec 8, 2006
Cancer Consultants (press release),Dr. Jean-Francois Rossi from Montpellier, France, has reported that the combination of Rituxan (rituximab) and Leukine (Sargramostim, GM-CSF) has significant ...

Pharmexa has started phase II trial in liver cancer with GV1001  -  Nov 28, 2006
PipelineReview.com (press release),...dose of the chemotherapeutic drug cyclophosphamide three days prior to the start of immunotherapy, followed by doses of GV1001 plus GM-CSF three times in the ...

SABCS: Breast Cancer Vaccine Seen Promising  -  Dec 15, 2006
MedPage Today,The vaccine was a peptide dubbed E75, derived from the HER2/neu protein and combined with granulocyte macrophage colony simulating factor (GM-CSF) and was ...

Phase II trial of GV1001 in lung cancer started  -  Dec 13, 2006
PipelineReview.com (press release),In the trial, GV1001 together with the adjuvant GM-CSF is tested in patients that prior to the treatment have been treated with chemotherapy and radiation ...

MicroIslet Expands Expertise in Product Development  -  Nov 30, 2006
PR Newswire (press release),...technology. Dr. Soo Hoo is the inventor of a technology for the generation and evaluation of membrane-bound GM-CSF cancer vaccines. "We ...

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional